An expert workgroup has developed the first appropriate use recommendations (AURs) for real-world use of the antiamyloid donanemab (Kisunla). “The role of appropriate use recommendations are to bridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback